Reach your audience. Get results.
Rely on the experience, guidance, and superior media targeting of Business Wire for your global press release distribution.
Public RelationsMaximize the reach of your news with our press release distribution services and partnerships. Investor RelationsReach and engage investors, shareholders, analysts, and media with our complete suite of IR services and tools. Distribution & AnalyticsTarget your news, reach your audiences, and understand the impact of your press releases with our analytics reports. |
Latest News
Today is September 23, 2024.
All times in Eastern Daylight Time.
-
Teva, partenaire de Medincell, a présenté de nouvelles données d'efficacité, de sécurité et de tolérance de l’essai pivot de phase 3 de l'olanzapine LAI pour les patients adultes atteints de schizophrénieMONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Teva a présenté à l’ENCP 2024* de nouvelles données positives d'efficacité, de sécurité et de tolérance de l’essai de phase 3 (SOLARIS) évalua... more »
-
LONDON--(BUSINESS WIRE)-- ANGLIAN WATER SERVICES FINANCING PLC GBP 35,000,000.00 MTN Floating Rate Notes Due 4/2031 ISSUE NAME. Our Ref. MJ8815 ISIN Code. GB00BYP7VR76 INTEREST AMT PER DENOM. CURR... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (th... more »
-
Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®MONTPELLIER, France--(BUSINESS WIRE)--New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-monthly Perseris® (RBP-7000) provided the mos... more »
-
More than 1,000 Tech Leaders Gather in Riyadh to Redefine the Future of IT at the IDC Saudi Arabia CIO Summit 2024RIYADH, Saudi Arabia--(BUSINESS WIRE)--The IDC Saudi Arabia CIO Summit 2024 brought together more than 1,000 of the kingdom's top IT decision makers this week at the Fairmont Riyadh. more »
-
Juniper Research: Who Leads the Digital Wallet Platform Market in 2024?BASINGSTOKE, England--(BUSINESS WIRE)--A new study from Juniper Research has revealed which platform providers lead the global digital wallets market in 2024. more »
-
LONDON--(BUSINESS WIRE)-- Malmo Stad Issue of NOK 700,000,000 Floating Rate Notes due March 2025 Series no 32 Tranche no 1 MTN ISSUE NAME. Our Ref. MM5004 ISIN Code. XS2108483046 INTEREST AMT PER ... more »
-
Medincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with SchizophreniaMONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Teva presented at ECNP 2024* new positive efficacy, safety, and tolerability results for Phase 3 SOLARIS trial evaluating Olanzapine LAI (TV-‘... more »
-
LONDON--(BUSINESS WIRE)-- City Of Goteborg Issue of SEK 300,000,000 Floating Rate notes Due September 2025 Series GB11 Tranche 1 MTN ISSUE NAME. Our Ref. MM2224 ISIN Code. XS2054601443 TOTAL INTER... more »
-
Wolters Kluwer Italia Achieves Gender Equality CertificationMILAN--(BUSINESS WIRE)--Wolters Kluwer Italia, a leader in professional information, software solutions, and services, today announced it has successfully obtained its Gender Equality Certification... more »
-
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 TrialTOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Topline results from the TROPION-Breast01 phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to investigator’s choice of chemotherapy, which p... more »
-
MONTPELLIER, France--(BUSINESS WIRE)--Teva presented at ECNP 2024* new positive efficacy, safety, and tolerability results for Phase 3 SOLARIS trial evaluating Olanzapine LAI (TV-‘749 / mdc-TJK) in... more »
-
Wolters Kluwer Italia ottiene la certificazione per la parità di genereMILANO--(BUSINESS WIRE)--Wolters Kluwer Italia, leader nel settore dell'informazione professionale, delle soluzioni software e dei servizi, ha annunciato oggi di aver ottenuto con successo la Certi... more »
-
Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris: MEDCL): New data presented by Teva at ECNP 2024* demonstrate switching to UZEDY at four weeks after the last dose of once-mo... more »